GLB1L3: A Potential Drug Target and Biomarker for Diseases (G112937)

Target Name: GLB1L3

NCBI ID: G112937

GLB1L3

GLB1L3: A Potential Drug Target and Biomarker for Diseases

GLB1L3 (GLBL3_HUMAN), a gene located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function in the body and its role in disease pathology have been extensively studied, and its potential as a drug target continue to attract researchers' interest.

GLB1L3 is a non-coding RNA molecule that is expressed in various tissues and cells of the body. It is a part of the gene family known as G-coupled proteins (GCPs), which are a family of cytoskeleton-associated proteins that play a crucial role in the structure and function of cells. GLB1L3 is a member of the GLB1 family, which includes several similar non-coding RNAs that are involved in the regulation of cell proliferation, differentiation, and survival.

The GLB1L3 gene has been shown to be involved in various cellular processes, including cell adhesion, migration, and survival. It has been shown to play a role in the regulation of mitochondrial function and to be involved in the development and progression of various diseases, including cancer.

GLB1L3 has also been shown to be a potential drug target for several diseases, including cancer. Cancer is a leading cause of death worldwide, and there is a significant need for new treatments to address the increasing number of cancer cases. GLB1L3 has been shown to be involved in the regulation of cell proliferation and has been potential target for anti-cancer drugs. For example, GLB1L3 has been shown to inhibit the growth of cancer cells in cell culture and animal models.

GLB1L3 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can cause a range of symptoms, including cognitive decline, memory loss, and behavioral changes. GLB1L3 has been shown to be involved in the regulation of neurotransmitter synthesis and function, which is important for the proper functioning of the brain.

GLB1L3 has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and pain. GLB1L3 has been shown to be involved in the regulation of immune cell function and has been potential target for anti-inflammatory drugs.

In conclusion, GLB1L3 is a non-coding RNA molecule that has been shown to be involved in various cellular processes and diseases. Its potential as a drug target continues to attract researchers' interest and its study may lead to new treatments for cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of GLB1L3 in disease and its potential as a drug target.

Protein Name: Galactosidase Beta 1 Like 3

The "GLB1L3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLB1L3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets